Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 1796 (106th)

Medicare Chronic Disease Prescription Drug Benefit Act of 1999

referredUnited States· United States Congress· EN

Introduced

13 May 1999

Last action

25 May 1999 · Referred

Status

Referred to the Subcommittee on Health and Environment.

Sponsors

Sen. Cardin, Benjamin L. [D-MD], Rep. Coyne, William J. [D-PA-14], Rep. Levin, Sander M. [D-MI-12], Rep. Stark, Fortney Pete [D-CA-13], Rep. Thurman, Karen L. [D-FL-5], Rep. Boucher, Rick [D-VA-9], Rep. Frost, Martin [D-TX-24], Rep. LaFalce, John J. [D-NY-29], Rep. Kennedy, Patrick J. [D-RI-1], Rep. Hooley, Darlene [D-OR-5], Rep. Gilchrest, Wayne T. [R-MD-1], Rep. Morella, Constance A. [R-MD-8], Rep. Owens, Major R. [D-NY-11], Rep. Minge, David [D-MN-2]

Subjects

Healthcare

Source updated

3 June 2026

Healthcare

Summary

Medicare Chronic Disease Prescription Drug Benefit Act of 1999 - Amends part B (Supplementary Medical Insurance) of title XVIII (Medicare) of the Social Security Act (SSA) to provide for Federal payments to a State non-Medicaid prescription drug benefit program on behalf of Medicare part B enrollees for certain prescription drugs (including insulin) and biological products for treatment of specified chronic conditions. Provides for the selection through competitive bidding of eligible providers of such prescription drugs and biological products (covered outpatient drugs) in a particular coverage area. Requires an eligible beneficiary not enrolled in a Medicare+Choice plan under Medicare part C (Medicare+Choice) to enroll with an eligible entity under this Act to be eligible to receive covered outpatient drugs under Medicare part B. Mandates appropriate outreach activities by the Secretary of Health and Human Services. Outlines cost-sharing requirements establishing an annual deductible of $250.00 and specified co-payments (with no co-payment for generic drugs). Allows the use of formularies, generic drug substitution, and other mechanisms to provide benefits economically. Directs the Secretary to: (1) establish a model for comprehensive educational programs to assure appropriate prescribing, dispensing, and use of such covered drugs; and (2) enter into an arrangement with the Institute of Medicine of the National Academy of Sciences for analysis of such new benefit and annual reports to the Secretary and Congress on its effectiveness in reducing demand for acute medical services, as well as its annual cost and resulting savings. Provides for appropriate funding for such analyses. Amends SSA title XIX (Medicaid) to provide for Medicaid coverage of the new Medicare part B prescription drug benefit cost-sharing for certain individuals who would be qualified Medicare beneficiaries but for their income which exceeds the level established by the State but is less than a certain percentage of the official poverty line for a family of the size involved.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 13 May 1999

    Introduced

    Referred to the Committee on Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  2. 13 May 1999

    Introduced

    Referred to the Committee on Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  3. 13 May 1999

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 13 May 1999

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 14 May 1999

    Introduced

    Sponsor introductory remarks on measure. (CR E968)

    Source: IntroReferral

  6. 20 May 1999

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  7. 25 May 1999

    Referred

    Referred to the Subcommittee on Health and Environment.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 13 May 1999

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 13 May 1999

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 13 May 1999

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.